Deciphering the influences of fetal programming on adult mental disorders causality depends on the identification of specific molecular pathways involved in their etiology. New insights will provide the means for reducing developmentally based disorder risk, and new therapeutic targets for treatments in adulthood. For example, our recent discovery of maternal–placental–fetal interactions that may influence brain development leads to new hypotheses regarding the mechanisms by which fetal programming of adult mental disorders may occur. A tryptophan (the precursor of serotonin—5-HT) metabolic pathway in the placenta (Bonnin et al, 2011) reflects the potential importance of extra-embryonically derived 5-HT in modulating developmental processes such as brain circuit wiring, thus affecting long-term brain function. This concept is consistent with classic genetic (5-HT1A knockout) and pharmacological (SSRI exposure) studies showing that disruption of 5-HT signaling transiently, during a restricted period of pre- or postnatal development, results in long-term behavioral abnormalities, such as increased anxiety in adulthood (Ansorge et al, 2008; Oberlander et al, 2009). Because many 5-HT receptors are expressed early and in complex temporal and spatial patterns during brain development (Bonnin et al, 2006), the full extent of the mechanisms through which disruption of 5-HT signaling leads to adult phenotypes is not yet understood. One possible route through which it could occur is the disruption of the modulatory activity of 5-HT signaling on fetal forebrain wiring. This was demonstrated in vitro via the modulation of netrin-1 axon guidance activity by 5-HT, and in vivo by simultaneous, targeted disruption of two 5-HT receptors (5-HT1B/1D) (Bonnin et al, 2007). Altered 5-HT signaling in the forebrain could preferentially influence wiring in this brain region in utero (Bonnin et al, 2007; Bonnin et al, 2011), ultimately leading to long-term dysfunction of circuits underlying mood and emotion. Control of 5-HT signaling, through the number and/or type of 5-HT receptors activated, may thus be critical for normal brain development.
During pregnancy, altered availability of 5-HT itself also may lead to abnormal signaling in the fetal brain. The newly discovered placenta-derived 5-HT accumulates in the fetal forebrain (but not the hindbrain; (Bonnin et al, 2011)). The period during which placental 5-HT reaches the forebrain in the mouse corresponds to the first and early second trimesters in the human, prenatal periods of neuronal migration, and initial circuit formation that are associated with greater risk for mental illnesses due to maternal perturbations. Thus, like other placenta-derived molecules (eg, growth factors), placental 5-HT output could be affected by both genetic (the embryo and placenta are genetically identical) and environmental disturbances that are known to increase risk for mental illnesses. In fact, altered tryptophan metabolism during pregnancy in mice has long-term functional consequences in the offspring, and has been implicated in increasing the risk for schizophrenia, bipolar disorder, and autism in humans (Miller et al, 2009). Although long-term follow-up studies are needed, prenatal exposure to SSRI antidepressants induces an array of disturbances in childhood. It is hypothesized that maternally ingested SSRIs cross the placental barrier and directly impact fetal brain development. However, as the serotonin transporter (SERT; Slc6a4) is also highly expressed in the placenta, SSRIs may impact placental function and have indirect effects on fetal development. The SSRIs impact on placental physiology at different stages of gestation is currently under investigation, using the newly developed ex vivo dual perfusion system for the mouse placenta (Bonnin et al, 2011).
These newest discoveries should stimulate further animal model and human research efforts to examine gene–environment influences during pregnancy that will address the developmental etiology of adult-onset mental disorders.
Acknowledgments
This work was supported by the NICHD (grant 5R21HD065287 to A.B.), NARSAD (to A.B.), and the NIMH (grant 1P50MH078280A1 to P.L.).
The authors declare no conflict of interest.
References
- Ansorge MS, Morelli E, Gingrich JA. Inhibition of serotonin but not norepinephrine transport during development produces delayed, persistent perturbations of emotional behaviors in mice. J Neurosci. 2008;28:199–207. doi: 10.1523/JNEUROSCI.3973-07.2008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bonnin A, Goeden N, Chen K, Wilson ML, King J, Shih JC, et al. A transient placental source of serotonin for the fetal forebrain. Nature. 2011;472:347–350. doi: 10.1038/nature09972. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bonnin A, Peng W, Hewlett W, Levitt P. Expression mapping of 5-HT1 serotonin receptor subtypes during fetal and early postnatal mouse forebrain development. Neuroscience. 2006;141:781–794. doi: 10.1016/j.neuroscience.2006.04.036. [DOI] [PubMed] [Google Scholar]
- Bonnin A, Torii M, Wang L, Rakic P, Levitt P. Serotonin modulates the response of embryonic thalamocortical axons to netrin-1. Nat Neurosci. 2007;10:588–597. doi: 10.1038/nn1896. [DOI] [PubMed] [Google Scholar]
- Miller CL, Murakami P, Ruczinski I, Ross RG, Sinkus M, Sullivan B, et al. Two complex genotypes relevant to the kynurenine pathway and melanotropin function show association with schizophrenia and bipolar disorder. Schizophr Res. 2009;113:259–267. doi: 10.1016/j.schres.2009.05.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Oberlander TF, Gingrich JA, Ansorge MS. Sustained neurobehavioral effects of exposure to SSRI antidepressants during development: molecular to clinical evidence. Clin Pharmacol Ther. 2009;86:672–677. doi: 10.1038/clpt.2009.201. [DOI] [PMC free article] [PubMed] [Google Scholar]